HK Stock Market Move | |JW THERAP-B (02126) Rebounds Over 8%; Company Clarifies Cost Dispute, Expects Unit Production Cost of Benlysta to Drop Over 65% Starting Next Year

date
14:20 18/11/2026
avatar
GMT Eight
JW THERAP-B (02126) rebounded over 8%. As of press time, it rose 8.11% to HK$2.465, with a turnover of HK$3.0189 million.
JW THERAP-B (02126) rebounded over 8%, rising 8.11% as of press time to HK$2.465, with turnover of HK$3.0189 million. On the news front, on November 18, JW Therapeutics' official WeChat account published a clarification statement regarding recent online remarks about the production costs and profitability of Benlysta. The company stated that the medical insurance payment standard for Benlysta is RMB288,600, effective from January 1, 2027. This payment standard is the result of the company's comprehensive consideration of the product's clinical value, patient accessibility, and sustainable corporate operations, reached after full communication with the national medical insurance authorities. With the advancement of independent supply of core raw materials such as lentiviral vectors, the localization and substitution of some raw materials and consumables, and the continuous improvement of production efficiency, the company expects that starting from 2027, the unit production cost of Benlysta will decrease by more than 65% compared with the actual level in 2025. In addition, cost reduction has always been premised on not lowering quality standards. Currently, the one-time preparation success rate of commercial production of Benlysta exceeds 99%.